{
    "body": "Which calcium channels does ethosuximide target?", 
    "documents": [
        "http://www.ncbi.nlm.nih.gov/pubmed/15638774", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21112351", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21596106", 
        "http://www.ncbi.nlm.nih.gov/pubmed/10882031", 
        "http://www.ncbi.nlm.nih.gov/pubmed/17291698", 
        "http://www.ncbi.nlm.nih.gov/pubmed/24933286", 
        "http://www.ncbi.nlm.nih.gov/pubmed/11641441", 
        "http://www.ncbi.nlm.nih.gov/pubmed/15078185", 
        "http://www.ncbi.nlm.nih.gov/pubmed/26089446", 
        "http://www.ncbi.nlm.nih.gov/pubmed/22924591", 
        "http://www.ncbi.nlm.nih.gov/pubmed/19005061", 
        "http://www.ncbi.nlm.nih.gov/pubmed/16171802", 
        "http://www.ncbi.nlm.nih.gov/pubmed/21148095"
    ], 
    "triples": [
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0033989", 
            "o": "D015220"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0034034", 
            "o": "D015220"
        }, 
        {
            "p": "http://www.w3.org/2004/02/skos/core#notation", 
            "s": "http://linkedlifedata.com/resource/umls/label/A0034035", 
            "o": "D015220"
        }
    ], 
    "ideal_answer": [
        "Ethosuximide blocks the T-type calcium channels."
    ], 
    "exact_answer": [
        "T-type calcium channels"
    ], 
    "concepts": [
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D020747", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D005013", 
        "http://www.nlm.nih.gov/cgi/mesh/2016/MB_cgi?field=uid&exact=Find+Exact+Term&term=D015220", 
        "http://www.biosemantics.org/jochem#4249275"
    ], 
    "type": "factoid", 
    "id": "56cf236f3975bb303a000002", 
    "snippets": [
        {
            "offsetInBeginSection": 463, 
            "offsetInEndSection": 685, 
            "text": "In the present study, we examined whether ethosuximide (ETX), a T-channel antagonist, could decrease the severity of ethanol withdrawal seizures by evaluating electrographical and behavioral correlates of seizure activity.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/24933286", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1315, 
            "offsetInEndSection": 1565, 
            "text": "In rats, intraplantar (i.pl.) administration of db-cAMP or PGE(2)  caused mechanical hyperalgesia, an effect suppressed by AKAPI, two distinct T-channel blockers, NNC 55-0396 and ethosuximide, or ZnCl(2) , known to inhibit Ca(v) 3.2 among T channels.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/22924591", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1059, 
            "offsetInEndSection": 1194, 
            "text": "Theta rhythms remained disrupted during a subsequent week of withdrawal but were restored with the T-type channel blocker ethosuximide.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21148095", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 223, 
            "offsetInEndSection": 604, 
            "text": "Given evidence that chemotherapy-induced neuropathic pain is blocked by ethosuximide, known to block T-type calcium channels, we examined if more selective T-type calcium channel blockers and also inhibitors of cystathionine-\u03b3-lyase (CSE), a major H\u2082S-forming enzyme in the peripheral tissue, are capable of reversing the neuropathic pain evoked by paclitaxel, an anti-cancer drug.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21596106", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 836, 
            "offsetInEndSection": 1073, 
            "text": "The results demonstrate that both ethosuximide and the active metabolite of methsuximide, alpha-methyl-alpha-phenylsuccinimide (MPS), block human T-type channels in a state-dependent manner, with higher affinity for inactivated channels.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11641441", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1293, 
            "offsetInEndSection": 1455, 
            "text": "T-type channels display current at the end of long pulses (persistent current), and this current was especially sensitive to block (ethosuximide IC(50) = 0.6 mM).", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/11641441", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 607, 
            "offsetInEndSection": 882, 
            "text": "We tested the effects of several T-type calcium channel blockers, including zonisamide (ZNS), ethosuximide, lomerizine, amiloride, mibefradil, and NCC 55-0396, a mibefradil derivative, on tacrine-induced tremulous jaw movements (TJMs), an animal model of parkinsonian tremor.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112351", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 112, 
            "text": "The antihyperalgesic effects of the T-type calcium channel blockers ethosuximide, trimethadione, and mibefradil.", 
            "beginSection": "title", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16171802", 
            "endSection": "title"
        }, 
        {
            "offsetInBeginSection": 505, 
            "offsetInEndSection": 595, 
            "text": "Gallopamil and another T-type-channel blocker, ethosuximide, were included for comparison.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10882031", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 1180, 
            "offsetInEndSection": 1256, 
            "text": "The Ca(v)3.2 channel is sensitive to ethosuximide, amlodipine and amiloride.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/15078185", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 0, 
            "offsetInEndSection": 214, 
            "text": "The purpose of the present study was to explore the analgesic effects of the low voltage-activated T-type Ca2+ channel blockers ethosuximide, trimethadione, and mibefradil in persistent and acute nociceptive tests.", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/16171802", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 335, 
            "offsetInEndSection": 611, 
            "text": "We tested the effects of several T-type calcium channel blockers, including zonisamide (ZNS), ethosuximide, lomerizine, amiloride, mibefradil, and NCC 55-0396, a mibefradil derivative, on tacrine-induced tremulous jaw movements (TJMs), an animal model of parkinsonian tremor. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/21112351", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 289, 
            "offsetInEndSection": 436, 
            "text": "We focused on two T-type calcium blockers, trimethadione and ethosuximide, which are anti-epileptics approved by the Food and Drug Administration. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/17291698", 
            "endSection": "abstract"
        }, 
        {
            "offsetInBeginSection": 418, 
            "offsetInEndSection": 509, 
            "text": "Gallopamil and another T-type-channel blocker, ethosuximide, were included for comparison. ", 
            "beginSection": "abstract", 
            "document": "http://www.ncbi.nlm.nih.gov/pubmed/10882031", 
            "endSection": "abstract"
        }
    ]
}